login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
KEZAR LIFE SCIENCES INC (KZR) Stock News
USA
- NASDAQ:KZR -
US49372L2097
-
Common Stock
6.18
USD
+0.14 (+2.32%)
Last: 11/10/2025, 12:07:19 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
KZR Latest News, Press Relases and Analysis
All
Press Releases
3 days ago - By: Kezar Life Sciences, Inc.
Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025
24 days ago - By: Benzinga
Kezar Launches Strategic Review As FDA Roadblock Derails Liver Drug Plans
24 days ago - By: Stocktwits
- Mentions:
DFAS
IWC
WFC
Kezar Life Sciences Stock Hit With Downgrades And Price Target Cuts: Retail Keeps Hopes Alive
24 days ago - By: Benzinga
- Mentions:
XRTX
ACHV
GNPX
RCEL
...
12 Health Care Stocks Moving In Friday's Intraday Session
3 months ago - By: The Motley Fool
Kezar Narrows Loss 37 Percent in Q2
25 days ago - By: Kezar Life Sciences, Inc.
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives
2 months ago - By: Zacks Investment Research
All You Need to Know About Kezar Life Sciences (KZR) Rating Upgrade to Buy
2 months ago - By: Kezar Life Sciences
Kezar Life Sciences to Participate in Two Upcoming Investor Conferences
3 months ago - By: Kezar Life Sciences, Inc.
Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update
4 months ago - By: Kezar Life Sciences, Inc.
Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis
6 months ago - By: Kezar Life Sciences, Inc.
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
6 months ago - By: Yahoo Finance
- Mentions:
PRME
EHC
NVDA
NPCE
...
Citi Downgrades Prime Medicine (PRME) to Neutral, Cuts PT to $1.50 Due to Market Uncertainty
6 months ago - By: Zacks Investment Research
Kezar Life Sciences (KZR) Upgraded to Buy: What Does It Mean for the Stock?
6 months ago - By: Kezar Life Sciences, Inc.
Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
8 months ago - By: Kezar Life Sciences, Inc.
Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results
8 months ago - By: Kezar Life Sciences, Inc.
Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025
9 months ago - By: Kezar Life Sciences, Inc.
Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025
a year ago - By: Kezar Life Sciences, Inc.
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
a year ago - By: Glancy Prongay & Murray LLP
Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)
a year ago - By: Kezar Life Sciences
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split
a year ago - By: Yahoo Finance
Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study
a year ago - By: Kezar Life Sciences
Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan
a year ago - By: Kezar Life Sciences, Inc.
Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update
a year ago - By: Kezar Life Sciences, Inc.
Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal
a year ago - By: Yahoo Finance
FDA Put Brakes On Penny Stock Kezar Life Sciences' Mid-Stage Study For Lead Development Candidate After Patient Deaths
a year ago - By: Kezar Life Sciences, Inc.
Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis
Please enable JavaScript to continue using this application.